tirzepatide court case US judge sides with FDA's removal of Lilly's weight loss drug from shortage list FDA Zepbound shortage ends, impacts

Researchers from Monell Chemical Senses Center have identified a specific population of neurons in the brain that could be key to appetite suppression without nausea, a common side effect of GLP-1 drugs like Ozempic and Wegovy.

Were DPP-4 inhibitors the original GLP-1s

90% (n=225) of patients were female, with an average age of 41.312 years

To address this growing global challenge, the World Health Organization (WHO) has developed a guideline on the use of glucagon-like peptide-1 (GLP-1) based therapies, including GLP-1 receptor agonists and GLP-1/GIP dual agonists, for adults living with obesity.Join us at the virtual launch event in a webinar hosted by WHO in collaboration with the Journal of the American Medical Association (JAMA) on 1 December 2025 at 16:00 CET